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Abstract
Aims/hypothesis The aim of this study was to prospectively
examine the association between body iron stores and risk of
type 2 diabetes.
Methods We designed a case–cohort study among 27,548
individuals within the population-based European Prospective
Investigation into Cancer and Nutrition (EPIC)-Potsdam study.
During 7 years of follow-up, 849 incident cases of type 2
diabetes were identified. Of these, 607 remained for analyses
after exclusion of participants with missing data or abnormal
glucose levels at baseline. A sub-cohort of 2,500 individuals
was randomly selected from the full cohort, comprising 1,969
individuals after applying the same exclusion criteria.
Results After adjustment for age, sex, BMI, waist circum-
ference, sports activity, bicycling, education, occupational
activity, smoking habit, alcohol consumption and circulating
levels of γ-glutamyltransferase, alanine aminotransferase,
fetuin-A, high-sensitivity C-reactive protein, adiponectin,
HDL-cholesterol and triacylglycerol, higher serum ferritin
concentrations were associated with a higher risk of type 2
diabetes (RR in the highest vs lowest quintile, 1.73; 95% CI
1.15, 2.61; ptrend00.002). No significant association was
observed for soluble transferrin receptor (RR 1.33; 95% CI
0.85, 2.09; ptrend00.50). The soluble transferrin receptor-to-
ferritin ratio was significantly inversely related to risk (RR
0.61; 95% CI 0.41, 0.91; ptrend00.02).
Conclusions/interpretation High ferritin levels are associated
with higher risk of type 2 diabetes independently of estab-
lished diabetes risk factors and a range of diabetes biomarkers
whereas soluble transferrin receptor concentrations are not
related to risk. These results support the hypothesis that higher
iron stores below the level of haemochromatosis are associ-
ated with risk of type 2 diabetes.
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Introduction
Impaired glucose metabolism and diabetes mellitus are com-
mon clinical manifestations of iron overload in patients with
haemochromatosis [1], a disorder of abnormal iron absorp-
tion resulting in the progressive accumulation of iron in
inner organs. The precise molecular mechanisms underlying
the pathogenesis of iron-overload-related diabetes have not
been identified but the initial glucose abnormalities include
insulin resistance and hyperinsulinaemia, followed by
impaired insulin secretion [2]. Elevated iron stores below
the levels of known iron overload syndromes have also
been implicated in the aetiology of diabetes [2, 3]. How-
ever, so far only a few studies have prospectively exam-
ined the association between body iron stores and risk of
diabetes [4–7].
Serum ferritin concentration is by far the most com-
monly used indicator of body iron stores in epidemio-
logical studies. The use of serum ferritin in assessing
iron stores, however, is complicated because ferritin is
also an acute-phase protein that may be elevated in
inflammation, liver disease and cancer [8]. Sub-clinical
inflammation, which is usually observed in individuals
with obesity and the metabolic syndrome, is associated
with increased risk of type 2 diabetes [9]. It is thus
unclear whether the association of ferritin with type 2
diabetes reflects these other abnormalities. Circulating
ferritin levels have also been shown to be positively
associated with circulating level of hepatic enzymes [4,
10] and markers of dyslipidaemia [11, 12], and nega-
tively associated with adiponectin levels [4]. Thus, in a
recent nested case–control study the association observed
between serum ferritin and diabetes risk disappeared after
adjustment for components of the metabolic syndrome
[13].
Furthermore, serum ferritin concentrations may not be an
accurate reflection of the intracellular iron pool, which is
likely to be responsible for iron-related oxidative stress [14].
Serum soluble transferrin receptor (sTfR) concentration has
been suggested as a more accurate measure of available
body iron [15, 16]. The level of circulating sTfR reflects
the availability of iron in the body and it can be used in the
clinical setting to distinguish between iron-deficiency
anaemia and anaemia due to chronic diseases [16]. When
the iron–transferrin complex binds to its cellular receptor
(TfR), iron enters cells and the soluble extracellular domain
of TfR is liberated into the circulation [17]. Serum levels of
this soluble form (sTfR) are therefore directly proportional
to tissue TfR concentration. Circulating sTfR levels corre-
late inversely with body iron stores and thus reflect, inver-
sely, intracellular iron storage, and the ratio of sTfR to
ferritin has been proposed as a preferred measure of body
iron stores to quantifiably reflect body iron over the entire
spectrum of iron balance [18, 19].
The objective of this study was to examine prospectively
the association of body iron stores, as assessed by circulating
ferritin concentrations and sTfR, as well as by the ratio of
sTfR to ferritin, with risk of incident type 2 diabetes in a
population-based cohort. We also investigated whether this
association is independent of inflammation as well as markers
of different metabolic pathways that may be involved in the
pathogenesis of type 2 diabetes.
Methods
Study population The EPIC-Potsdam study is part of the
multicentre European Prospective Investigation into Cancer
and Nutrition (EPIC) [20, 21]. In Potsdam, Germany,
27,548 individuals (16,644 women mainly aged 35–65 years
and 10,904 men mainly aged 40–65 years) were recruited
from the general population between 1994 and 1998
[22]. The baseline examination included anthropometric
measurements, a personal health interview, a health ques-
tionnaire and blood sampling. Informed consent was
obtained from participants; approval was given by the
Ethics Committee of the Medical Association of the State of
Brandenburg, Germany.
The health interview and the questionnaire elicited infor-
mation on educational attainment, smoking and alcohol
consumption habits, and occupational and leisure-time
physical activity. The latter was assessed as sports activity
and cycling, both calculated as the average time spent per
week during the 12 months before recruitment. Waist cir-
cumference was measured midway between the lower rib
margin and the superior anterior iliac spine to the nearest
0.5 cm with a non-stretching tape applied horizontally [23].
Weight and height were measured without shoes in light
clothing and BMI was calculated as kg/m2.
The prevalence of diabetes at baseline was evaluated by a
physician using information on self-reported medical diag-
noses, medication records and ongoing nutritional therapy.
Uncertainties regarding a proper diagnosis were clarified
with the participant or their physician.
Incident cases of diabetes were identified during follow-
up until 31 August 2005 via self-reports of a diabetes
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diagnosis, diabetes-relevant medication or dietary treatment
related to diabetes. All incident cases were verified by
questionnaires mailed to the diagnosing physician, request-
ing details of the date and type of diagnosis, diagnostic tests
and treatment of diabetes. Only individuals with a diagnosis
of type 2 diabetes that was confirmed by a physician (ICD-
10; www.who.int/classifications/icd/en/) and a diagnosis
date after the baseline examination were considered as inci-
dent cases of type 2 diabetes.
Our study was conducted in a prospective case–cohort
design [24]. For this, we selected a sub-cohort of 2,500
individuals from all participants in the EPIC-Potsdam study
who provided blood samples at baseline (n026,444). Of
these, 1,969 participants remained for analyses after exclud-
ing participants with any history of diabetes at baseline or
with self-reported but unverified diabetes during follow-up,
with missing values for study variables or with abnormal
plasma glucose (random glucose 11.1 mmol/l or more, or
fasting glucose 7.0 mmol/l or more, or less than 2.8 mmol/l).
By randomly selecting a sub-cohort and using appropriate
statistics for this research design, the results are expected to
be generalisable to the entire cohort without the need of
biomarker measurements in the entire EPIC-Potsdam study.
During an average follow-up time of 7 years, a total of 849
incident cases of type 2 diabetes were identified in the full
cohort. Of these, 607 remained for analyses after applying
similar exclusion criteria. In agreement with the case–cohort
design, 56 individuals who developed type 2 diabetes during
follow-up were identified in the sub-cohort (so called inter-
nal cases [24]), while 551 incident cases were identified
outside the sub-cohort (external cases).
Clinical and biomarker measurements A total of 30 ml of
venous blood was collected at baseline from partici-
pants; it was fractionated into serum, plasma, buffy coat
and erythrocytes and was liquated into straws and stored
in liquid nitrogen at 170°C for conservation until the
time of analysis. Serum and plasma samples were trans-
ferred to the Department of Internal Medicine, Univer-
sity of Tübingen, on dry ice for analyses. Serum ferritin
concentrations were determined using an ADVIA Cen-
taur XP and serum sTfR concentrations using a BN
ProSpec System (both Siemens Healthcare, Erlangen,
Germany). Plasma levels of alanine aminotransferase (ALT),
γ-glutamyltransferase (GGT), HDL-cholesterol, triacylgly-
cerol and high-sensitivity C-reactive protein (hs-CRP) were
determined using the automatic ADVIA 1650 analyser (Sie-
mens Medical Solutions, Erlangen, Germany). Total adipo-
nectin concentration was measured using an ELISA (Linco
Research, St Charles, MI, USA). For determination of
fetuin-A an immunoturbidimetric method was used with
specific polyclonal goat anti-human fetuin-A antibodies to
human fetuin-A (BioVendorLaboratoryMedicine,Modreci,
Czech Republic) [25]. Erythrocyte levels of HbA1c were
measured using an HPLC procedure according to the man-
ufacturer's instructions (Tosoh, Stuttgart, Germany).
Total adiponectin concentration was measured using an
ELISA (Linco Research). All assay procedures were
performed as described by the manufacturer.
Statistical analysis The correlation between biomarkers of
body iron stores and diabetes risk factors was studied in
the sub-cohort with age- and sex-adjusted partial Pearson
correlation coefficients. Skewed variables were log-
transformed. Circulating levels of ferritin, sTfR and the
ratio of sTfR to ferritin were categorised into sex-specific
quintiles based on sub-cohort participants. The RR of type 2
diabetes with 95% CI for quintiles of measures of body iron
stores was calculated using the proportional hazards model,
modified for the case–cohort design according to the Prentice
method [24]. Age at baseline in 1-year categories was entered
as a stratum variable. Age was also used as an underlying time
variable in the counting processes, with entry defined as the
participant’s age at recruitment and exit defined as age at
diabetes diagnosis or censoring. Models were adjusted for
sex, BMI (continuous), waist circumference (continuous),
education (in or no training, vocational training, technical
school, or technical college or university degree), occupa-
tional activity (light, moderate or heavy), sports activity (0,
0.1–4 or over 4 h/week), cycling (0, 0.1–2.4, 2.5–4.9 or 5 or
more h/week), smoking habit (never, past, current ≤20 ciga-
rettes/day or current >20 cigarettes/day) and alcohol intake (0,
0.1–5, 5.1–10, 10.1–20, 20.1–40 or over 40 g/day). In further
models, we additionally adjusted for metabolic biomarkers
(hs-CRP; GTTandALT; HDL-cholesterol and triacylglycerol;
and adiponectin, all continuous). In addition, a model includ-
ing energy intake and consumption of coffee, red meat and
whole-grain bread was used. In additional analyses we
excluded individuals (n046) in whom serum ferritin was
elevated beyond three times the SD from the mean (25
women with ferritin over 37.3 mg/l, 21 men with ferritin
over 100.0 mg/l) to reduce the possibility of including
those with undiagnosed obvious haemochromatosis. Tests
of linear trends in RR across quintiles of the biomarker
levels were carried out by including the quintile of iron
store variable in the model as a continuous variable. Since
no evidence of a statistical interaction between measures
of body iron and sex was observed in a model including
an interaction term, the analyses were performed in men
and women combined (p for interaction 0.80, 0.24 and
0.69 for ferritin, sTfR and the ratio of sTfR to ferritin,
respectively).
All p values presented are two-tailed, and p<0.05 was
considered statistically significant. All analyses were per-
formed using SAS software (version 9.1; SAS Institute Inc,
Cary, NC, USA).
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Results
Baseline characteristics across quintiles of ferritin in the
random sub-cohort are presented in Table 1. Participants
with higher ferritin concentrations tended to be older,
more inactive and have a higher BMI and waist circum-
ference, and they reported higher alcohol consumption
compared with participants who had lower ferritin con-
centrations. Consumption of red meat and coffee increased
across quintiles of serum ferritin, while consumption of
whole-grain bread decreased. Concentrations of the hep-
atic enzymes ALT and GGT, as well as hs-CRP and
triacylglycerol, were higher with increasing ferritin cate-
gories, whereas adiponectin and HDL-cholesterol concen-
trations were lower.
The markers of iron stores were weakly to moderately
correlated with other metabolic biomarkers and with BMI and
waist circumference (Table 2). For example, the age- and sex-
adjusted partial Pearson coefficients for the correlations of waist
circumferencewith ferritin, sTfR and sTfR-to-ferritin ratio were
0.23 (p<0.001), 0.11 (p<0.001) and −0.18 (p<0.001),
respectively.
A significant association was observed between serum
ferritin concentration and type 2 diabetes risk (Table 3). The
relative risk in the highest compared with the lowest quintile
of ferritin was 2.00 (95% CI 1.35, 2.95; ptrend< 0.001) when
adjusted for age, sex, BMI, waist circumference, sports activ-
ity, bicycling, education, occupational activity, smoking habit
and alcohol consumption. We next examined the impact of
adjustment for different biomarkers on the association of
measures of iron status with risk of type 2 diabetes. In these
analyses, adjustment for GGT and ALT tended to have the
strongest effect in terms of attenuating the risk for the associ-
ation of ferritin with risk of diabetes, whereas adjustment for
hs-CRP tended to have a weaker effect. Results remained
virtually unchanged when hs-CRP was adjusted for in estab-
lished risk categories (<1, 1–3, ≥3mg/l) [26] instead of using a
linear term. Although mutual adjustment for hs-CRP, GGT,
ALT, adiponectin, HDL-cholesterol and triacylglycerol fur-
ther attenuated the association, it still remained significant.
Table 1 Characteristics of study participants according to quintiles of plasma ferritin level in the sub-cohort
Characteristic Quintiles of plasma ferritina
1 (n0377) 2 (n0394) 3 (n0389) 4 (n0398) 5 (n0411)
Age (years), mean (SD) 47.1 (8.74) 48.1 (8.73) 48.9 (8.86) 51.4 (8.63) 54.6 (8.16)
Sex (% men) 39.3 34.0 36.5 40.5 38.2
Current or former smoker (%) 54.4 53.8 50.4 50.0 52.1
University degree education (%) 40.6 37.8 42.4 37.7 31.1
BMI (kg/m2), mean (SD) 24.7 (3.59) 25.0 (4.09) 26.1 (3.97) 26.2 (4.15) 27.8 (4.51)
Waist circumference (cm), mean (SD) 81.8 (11.46) 82.2 (12.3) 85.5 (12.4) 86.3 (11.9) 90.6 (12.8)
Alcohol consumption (g/day), mean (SD) 13.1 (16.18) 11.2 (12.5) 13.6 (19.9) 15.1 (17.9) 17.0 (29.1)
Sports activity (h/week), mean (SD) 1.33 (2.26) 1.05 (1.64) 1.04 (1.76) 1.03 (1.79) 0.69 (1.29)
Bicycling (h/week), mean (SD) 1.87 (2.73) 1.76 (2.89) 1.48 (2.22) 1.99 (2.88) 1.86 (3.06)
Heavy or very heavy work strain (%) 5.84 5.58 5.40 6.03 8.03
Energy intake (kJ/day), mean (SD) 8,986 (2847) 8,642 (2731) 8,543 (2506) 8,647 (2688) 8,459 (2874)
Red meat (servings/day), mean (SD) 0.26 (0.20) 0.28 (0.19) 0.28 (0.19) 0.29 (0.18) 0.30 (0.20)
Whole-grain bread (servings/day), mean (SD) 0.96 (1.03) 0.96 (1.05) 0.97 (1.14) 0.94 (1.15) 0.77 (0.98)
Coffee (cups/day), mean (SD) 2.78 (2.39) 2.74 (1.82) 2.75 (2.12) 2.86 (2.15) 2.81 (2.00)
Plasma levels, geometric mean (95% CI)
sTfR (mg/l) 1.09 (1.06, 1.12) 1.00 (0.98, 1.02) 0.98 (0.96, 1.00) 1.00 (0.98, 1.02) 1.02 (1.00, 1.04)
sTfR/ferritin ratio 0.58 (0.53, 0.64) 0.23 (0.22, 0.25) 0.13 (0.12, 0.14) 0.08 (0.08, 0.09) 0.04 (0.04, 0.05)
Adiponectin (ng/ml) 7.39 (7.05, 7.76) 7.26 (6.92, 7.62) 7.30 (6.94, 7.67) 7.15 (6.81, 7.51) 7.02 (6.68, 7.38)
GGT (U/l) 14.1 (13.0, 15.2) 14.7 (13.7, 15.7) 18.6 (17.1, 20.3) 19.3 (17.9, 20.9) 25.4 (23.3, 27.8)
ALT (U/l) 17.2 (16.5, 18.0) 17.7 (16.9, 18.5) 19.4 (18.5, 20.4) 19.6 (18.7, 20.5) 24.1 (22.8, 25.5)
Fetuin-A (μg/ml) 250 (245, 256) 247 (240, 253) 245 (238, 253) 243 (238, 249) 237 (232, 243)
hs-CRP (mg/l) 0.52 (0.45, 0.59) 0.55 (0.48, 0.63) 0.80 (0.70, 0.90) 0.87 (0.76, 0.99) 1.02 (0.89, 1.16)
HDL-cholesterol (mmol/l) 1.34 (1.31, 1.38) 1.35 (1.32, 1.39) 1.32 (1.28, 1.36) 1.29 (1.26, 1.32) 1.26 (1.23, 1.30)
Triacylglycerol (mmol/l) 1.07 (1.01, 1.13) 1.02 (0.97, 1.08) 1.17 (1.11, 1.23) 1.26 (1.19, 1.34) 1.40 (1.32, 1.48)
a Ferritin quintiles for men were <8.00, 8.00 to <13.0, 13.0 to <19.0, 19.0 to <28.0 and ≥28.0 mg/l; and for women ferritin quintiles were <2.00,
2.00 to <3.89, 3.89 to <6.39, 6.39 to <11.0, and ≥11.0 mg/l
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Specifically, the RR for the extreme quintile of ferritin was
1.60 (95% CI 1.07, 2.41; ptrend00.007). In contrast to ferritin,
no significant association was observed between serum levels
of sTfR and type 2 diabetes risk. The corresponding multi-
variate RR for the highest vs lowest quintile of sTfR was 1.22
(95% CI 0.81, 1.86; ptrend00.64). Further adjustment for
ferritin did not notably alter the result (data not shown).
Finally, a significant inverse association was observed
between sTfR-to-ferritin ratio and type 2 diabetes risk in
models adjusting for various lifestyle factors (RR 0.50; 95%
CI 0.34, 0.73; ptrend<0.001). Only marginal changes in risk
estimates were observed in models further adjusting for
different biomarkers. In a final model including markers
of inflammation and dyslipidaemia, as well as adiponectin
and liver enzymes, the RR for extreme quintiles of sTfR-to-
ferritin ratio was 0.61 (95% CI 0.41, 0.91; ptrend00.02).
Further adjustment for dietary factors, including energy
intake, consumption of red and processed meat, coffee,
whole-grain bread, magnesium and dietary iron did not
notably alter the associations observed for ferritin and
sTfR-to-ferritin ratio (data not shown); neither did further
adjustment for circulating HbA1c level (data not shown).
When we excluded 46 individuals with serum ferritin
levels greater than or equal to three times the SD from the
mean, no notable alteration in the results was observed (data
not shown). Results were also not substantially different
when we excluded 157 cases of type 2 diabetes that
occurred within the first 2 years of follow-up (to further
reduce the possibility of including individuals with undiag-
nosed diabetes at baseline) (data not shown). In further
exploratory analyses we investigated potential effect mod-
ification of HbA1c level, BMI, hs-CRP level or hyperten-
sion. We found a significant interaction for circulating
HbA1c level on the association between ferritin and diabetes
risk (pinteraction<0.001). Thus, the association observed
between serum ferritin level and diabetes risk was signifi-
cant among persons with HbA1c of 5.3% (34.4 mmol/mol)
or more (RR for the highest quintile 1.70; 95% CI 1.03,
2.80), but not among persons with HbA1c values below
5.3% (34.4 mmol/mol) (RR for the highest quintile 0.97;
CI 0.38, 2.50). Circulating HbA1c also tended to modify the
association between sTfR and diabetes risk, albeit the inter-
action term did not reach the significance level of 0.05
(pinteraction00.08). Thus, among participants with an
HbA1c level above 5.3% (34.4 mmol/mol), the RR for
the highest vs lowest quintile was 1.15 (95% CI 0.69,
1.91), whereas for HbA1c levels below 5.3% (34.4 mmol/
mol) it was 2.39 (95%CI 0.79, 7.23). We found no significant
interaction of ferritin, sTfR and the sTfR-to-ferritin ratio
with BMI, hs-CRP level or hypertension, on risk of type 2
diabetes (data not shown).
Discussion
In the present case–cohort study, higher body iron stores
(reflected by elevated ferritin concentration and a lower ratio
of sTfR to ferritin) were associated with increased risk of
type 2 diabetes. These associations remained significant
after adjustment for a wide range of known risk factors
and markers of different pathways of the development of
diabetes. Of the individual markers, adjustment for ALT and
GGT had the strongest impact on the association observed
between ferritin and diabetes risk. In contrast, only a
marginal impact on the inverse association between
sTfR-to-ferritin ratio and type 2 diabetes was observed
in models adjusting for biomarkers of inflammation, hepatic
fat accumulation, insulin resistance and dyslipidaemia. Levels
of sTfR were not significantly associated with risk of type 2
diabetes.
Table 2 Age and sex adjusted
partial Pearson correlation
coefficients between serum
levelsa of iron markers and
biomarkers of selected risk
factors of diabetes in the
sub-cohort
No. of individuals included in
sub-cohort, n01,969
aBased on log-transformed
values of biomarkers
Ferritin sTfR sTfR/ferritin ratio
Marker or biomarker r p value r p value r p value
sTfR −0.16 <0.001
sTfR/ferritin ratio −0.97 <0.001 0.41 <0.001
BMI 0.21 <0.001 0.10 <0.001 −0.17 <0.001
Waist circumference 0.23 <0.001 0.11 <0.001 −0.18 <0.001
Red meat intake 0.09 <0.001 0.01 0.51 −0.08 <0.001
Adiponectin −0.08 <0.001 0.02 0.32 0.08 <0.001
GGT 0.26 <0.001 0.08 <0.001 −0.22 <0.001
ALT 0.24 <0.001 0.07 0.003 −0.21 <0.001
Fetuin-A −0.04 0.07 0.08 <0.001 0.06 0.01
hs-CRP 0.16 <0.001 0.04 0.11 −0.14 <0.001
HDL-cholesterol −0.08 <0.001 −0.03 0.14 0.07 0.003
Triacylglycerol 0.13 <0.001 0.03 0.20 −0.15 <0.001
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The results of the present study are consistent with findings
from previous prospective studies suggesting that high serum
ferritin concentrations [4–6, 13] and lower ratios of sTfR to
ferritin [5, 7] are associated with increased risk of type 2
diabetes. Specifically, in a prospective study among Finnish
men, Salonen et al [7] observed a 2.5-fold higher risk of
diabetes among persons in the lowest compared with the
highest quintile of sTfR-to-ferritin ratio; however, their anal-
ysis was not adjusted for markers of inflammation, liver
enzymes or adiponectin. In the Nurses’ Health Study [5],
serum ferritin levels and the sTfR-to-ferritin ratio were asso-
ciated with an approximately 2.5-fold higher diabetes risk in
the highest vs lowest quintile after controlling for C-reactive
protein and various conventional risk factors of diabetes. In
the EPIC-Norfolk cohort [4], higher ferritin level was associ-
ated with diabetes risk after adjustment for conventional risk
factors as well as plasma levels of vitamin C, C-reactive
protein, fibrinogen, IL-6, liver function tests, ALT, GGT and
adiponectin. In contrast to these studies, in the ARIC cohort
the association was not significant after adjustment for HDL-
cholesterol, waist circumference, hypertension, fasting glu-
cose level and fasting triacylglycerol level [13]. In the present
study, we were able to investigate the association of body iron
stores, as assessed not only as circulating ferritin concentra-
tions but also as sTfR (and the ratio of sTfR to ferritin), with
risk of incident type 2 diabetes in a population-based cohort.
Table 3 RR of type 2 diabetes (95% CI) according to serum ferritin, sTfR and the ratio of sTfR to ferritin
Risk factor RR (95% CI) ptrend
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Ferritin
Men, mg/l <8.00 8.00 to <13.0 13.0 to <19.0 19.0 to <28.0 ≥28.0
Women, mg/l <2.00 2.00 to <3.89 3.89 to <6.39 6.39 to <11.0 ≥11.0
Model 1 1 0.95 (0.59, 1.50) 1.49 (1.00, 2.24) 1.54 (1.03, 2.31) 2.00 (1.35, 2.95) <0.001
Model 1 + hs-CRP 1 1.01 (0.63, 1.63) 1.56 (1.03, 2.37) 1.65 (1.09, 2.50) 2.09 (1.40, 3.12) <0.001
Model 1 + GGT and ALT 1 0.91 (0.57, 1.46) 1.45 (0.97, 2.17) 1.51 (1.01, 2.26) 1.74 (1.17, 2.60) <0.001
Model 1 + fetuin-A 1 0.94 (0.59, 1.51) 1.53 (1.01, 2.30) 1.58 (1.05, 2.38) 2.13 (1.43, 3.16) <0.001
Model 1 + adiponectin 1 0.92 (0.57, 1.49) 1.52 (1.00, 2.30) 1.55 (1.03, 2.33) 1.95 (1.31, 2.90) <0.001
Model 1 + HDL-cholesterol, triacylglycerol 1 1.00 (0.62, 1.61) 1.49 (0.99, 2.25) 1.49 (0.99, 2.23) 1.80 (1.22, 2.66) <0.001
Model 2 1 1.00 (0.61, 1.65) 1.49 (0.97, 2.30) 1.59 (1.05, 2.42) 1.73 (1.15, 2.61) 0.002
sTfR
Men, mg/l <0.90 0.90 to <1.00 1.00 to <1.10 1.10 to <1.30 ≥1.30
Women, mg/l <0.80 0.80 to <0.89 0.89 to <1.00 1.00 to <1.20 ≥1.20
Model 1 1 1.37 (0.89, 2.12) 1.83 (1.20, 2.79) 1.52 (1.03, 2.24) 1.22 (0.81, 1.86) 0.64
Model 1 + hs-CRP 1 1.42 (0.92, 2.19) 1.87 (1.23, 2.85) 1.51 (1.02, 2.23) 1.18 (0.78, 1.80) 0.85
Model 1 + GGT and ALT 1 1.33 (0.86, 2.07) 1.81 (1.19, 2.76) 1.46 (0.99, 2.16) 1.19 (0.78, 1.81) 0.75
Model 1 + fetuin-A 1 1.36 (0.88, 2.10) 1.78 (1.17, 2.71) 1.48 (1.00, 2.18) 1.14 (0.75, 1.73) 0.94
Model 1 + adiponectin 1 1.40 (0.89, 2.20) 1.81 (1.17, 2.81) 1.63 (1.09, 2.45) 1.30 (0.84, 2.00) 0.38
Model 1 + HDL-cholesterol, triacylglycerol 1 1.47 (0.94, 2.30) 1.93 (1.25, 2.97) 1.50 (1.00, 2.23) 1.36 (0.89, 2.08) 0.47
Model 2 1 1.38 (0.86, 2.20) 1.87 (1.20, 2.93) 1.47 (0.97, 2.22) 1.21 (0.78, 1.89) 0.80
sTfR-to-ferritin ratio
Men, (mg/l)/(mg/l) <0.04 0.04 to <0.05 0.05 to <0.08 0.08 to <0.13 ≥0.13
Women, (mg/l)/(mg/l) <0.09 0.09 to <0.15 0.15 to <0.25 0.25 to <0.50 ≥0.50
Model 1 1 0.66 (0.48, 0.90) 0.59 (0.43, 0.82) 0.63 (0.45, 0.88) 0.50 (0.34, 0.73) <0.001
Model 1 + hs-CRP 1 0.67 (0.49, 0.91) 0.59 (0.42, 0.82) 0.63 (0.45, 0.89) 0.47 (0.32, 0.70) <0.001
Model 1 + GGT and ALT 1 0.72 (0.52, 0.99) 0.66 (0.47, 0.91) 0.69 (0.49, 0.98) 0.56 (0.38, 0.83) 0.004
Model 1 + fetuin-A 1 0.64 (0.46, 0.87) 0.57 (0.41, 0.79) 0.58 (0.41, 0.82) 0.46 (0.32, 0.68) <0.001
Model 1 + adiponectin 1 0.71 (0.51, 0.97) 0.62 (0.44, 0.87) 0.64 (0.45, 0.92) 0.52 (0.35, 0.76) <0.001
Model 1 + HDL-cholesterol, triacylglycerol 1 0.69 (0.50, 0.95) 0.64 (0.46, 0.89) 0.71 (0.50, 1.00) 0.55 (0.37, 0.80) 0.002
Model 2 1 0.76 (0.54, 1.06) 0.67 (0.47, 0.96) 0.70 (0.48, 1.02) 0.57 (0.38, 0.85) 0.005
Model 1 is adjusted for age, sex, BMI, waist circumference, sports activity, bicycling, education, occupational activity, smoking habit and alcohol
consumption
Model 2 is adjusted for factors in model 1 and GGT, ALT, fetuin-A, hs-CRP, adiponectin, HDL-cholesterol and triacylglycerol concentrations
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In addition, we were able to account for potential confounding
effects of a wide range of biomarkers presenting different
pathways leading to onset of type 2 diabetes (including hs-
CRP, adiponectin, GGT, ALT, fetuin-A, HDL-cholesterol and
triacylglycerol), some of which were not accounted for in
previous studies. Generally, risk estimates between measures
of body iron status and type 2 diabetes were attenuated after
inclusion of biomarkers. Exceptions were C-reactive protein
and fetuin-A, for which risk estimates increased; however, the
increase was small and lay within the limits of uncertainty. We
were also able to adjust for circulating HbA1c, which, however,
as a measure of long-term blood glucose levels, can be con-
sidered a rather downstream marker of onset of disease rather
than a metabolic pathway to type 2 diabetes. Therefore, we
excluded HbA1c levels from the main analysis. Interestingly,
though, the relative contributions of the biomarkers were not
substantially different when we further adjusted for HbA1c
levels in sensitivity analyses.
Two prospective studies that evaluated the association
between ferritin and diabetes incidence also measured sTfR
levels and reported that not only a high ferritin level but also
a low sTfR-to-ferritin ratio was significantly associated with
an increased risk of diabetes [5, 7]. However, the indepen-
dent association between sTfR levels per se and diabetes risk
was reported only in one study. That study, conducted
within the placebo arm of the Diabetes Prevention Program,
suggested that elevated sTfR levels are associated with
increased risk of diabetes among overweight and obese
persons with impaired glucose tolerance [6]. The authors
speculated that sTfR levels may increase as a compensatory
mechanism for a reduction in free iron levels that may occur
secondary to oxidative stress. Alternatively, the authors
suggested that sTfR may be a biomarker of some other
factor that is causally related to development of diabetes,
possibly unrelated to iron load. In the present study, we
found no association between sTfR and diabetes incidence.
Interestingly, sTfR tended to be associated with diabetes risk
in individuals with HbA1c values below median but not in
those with above-median HbA1c values. In the present study
circulating levels of sTfR were remarkably lower (average
1.13 mg/l) than those observed in the Diabetes Prevention
Program (average 3.4 mg/l). Thus, it is possible that in the
present study the contrast between low and high values was
too small to reveal an association with increased risk.
The mechanism for the association between ferritin and
type 2 diabetes is unknown, but excess iron is usually stored
in the liver, muscle and pancreas and may cause organ-
specific oxidative stress leading to insulin resistance and
beta cell failure. Iron is a catalyst in the formation of
hydroxyl radicals, which are highly active and potentially
attack cell membrane lipids [27], and subsequent changes in
cell membrane may lead to impaired glucose intake of the
cell [28, 29]. In the liver, damage due to oxidative stress
may cause insulin resistance by interfering with the ability
of insulin to suppress hepatic glucose production [30]. The
hepatic insulin resistance caused by iron overload seems to
be independent of insulin resistance induced by fatty liver
disease [31]. In addition, iron accumulation in hepatocytes
may interfere with the insulin-extracting capacity of the
liver, while iron accumulation also interferes with insulin
synthesis and secretion in the pancreas [2]. Hence, iron
excess seems to contribute initially to insulin resistance
and subsequently to decreased insulin secretion [2]. In
addition, iron deposition in muscle has been shown to
decrease glucose uptake [32]. Although elevated plasma
ferritin levels may be causally related to risk of diabe-
tes, increased ferritin levels may also be a marker of
metabolic alterations that may causally increase diabetes
risk. For example, increased ferritin values may reflect
subclinical systemic inflammation [1, 33], fatty liver
[34, 35] or dyslipidaemia [11, 12], which are all poten-
tially related to insulin resistance and risk of type 2 diabetes.
However, in the present study the association observed
between ferritin and risk of diabetes was independent of bio-
markers of inflammation, hepatic fat accumulation, insulin
resistance and dyslipidaemia.
Circulating ferritin concentrations are commonly used as an
indicator of body iron stores in epidemiological studies. This
use, however, is complicated, because ferritin is an acute-phase
protein that may be elevated in inflammation, severe liver
disease or cancer [8]. Furthermore, its relationship to non-
transferring bound iron and the intracellular iron pool, which
may be responsible for iron-related oxidative damage, is uncer-
tain [14]. Circulating sTfR concentration has been proposed as
a marker of iron status that is less affected by the presence of
inflammation. However, low iron stores result in the induction
of synthesis of TfRs and they also reflect iron requirement [36].
Therefore, it has been suggested that the ratio of serum con-
centrations of sTfR and ferritin should be a preferred measure
of body iron stores [18, 19, 37]. However, in the present study
no notable difference in the strength of the associations with
diabetes risk was observed between ferritin and sTfR-to-ferritin
ratio. Given that a strong inverse correlation (r0−0.97) was
observed between ferritin and sTfR-to-ferritin ratio, and no
association was observed for sTfR, the association observed
for sTfR-to-ferritin ratio is likely to be driven by ferritin only.
On the other hand it can be speculated that if sTfR was a more
accurate marker of iron stores, then this would indicate that iron
stores are not a relevant risk factor for the development of
diabetes and that ferritin concentration might reflect something
different not fully accounted for in the present–as well as in
previous–studies showing a strong association between ferritin
and diabetes risk.
All potential cases in our study were verified by a physi-
cian. Although we considered only clinically apparent type 2
diabetes and did not screen our study population during
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follow-up, we excluded participants with plasma glucose val-
ues within the diabetic range at baseline, and exclusion of
individuals diagnosed within the first 2 years of follow-up did
not alter the result. Thus, it is unlikely that prevalent but
undiagnosed cases of diabetes have influenced the results. A
number of participants were excluded from the original study
population for the present analysis. However, excluded
cases and non-cases did not differ from those cases and
non-cases included in the analysis and we therefore do
not expect an influence of exclusion on the risk esti-
mates. We had data available from a single blood with-
drawal only, which might have introduced random
measurement errors in determining biomarkers. Random
measurement error generally tends to bias relative risks
in epidemiological studies between biomarkers and dis-
ease outcomes towards the null [38]. Also, additional
sources of measurement variability (related to blood
processing or long-term storage) may have differed
between the biomarkers. Thus, we cannot entirely rule
out the possibility that some of the above-mentioned limita-
tions may have influenced our results. Although the analyses
were adjusted for a large variety of known diabetes risk
factors, we cannot rule out the possibility that our observations
may have been influenced by other unmeasured factors or by
residual confounding due to imprecision in the measurement
of covariates.
In conclusion, we found that elevated body iron stores
below the levels observed in haemochromatosis are associated
with higher risk of type 2 diabetes independently of established
risk factors and a range of diabetes biomarkers. However, sTfR
levels were not associated with type 2 diabetes and our find-
ings imply that particularly high ferritin levels are related to a
higher risk of type 2 diabetes. Further research is warranted to
identify predictors of ferritin concentrations, which may help
to identify targets for lowering the risk of type 2 diabetes.
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